WO2002030411A8 - Treatment of apoptotic cell death - Google Patents

Treatment of apoptotic cell death

Info

Publication number
WO2002030411A8
WO2002030411A8 PCT/US2001/031992 US0131992W WO0230411A8 WO 2002030411 A8 WO2002030411 A8 WO 2002030411A8 US 0131992 W US0131992 W US 0131992W WO 0230411 A8 WO0230411 A8 WO 0230411A8
Authority
WO
WIPO (PCT)
Prior art keywords
cell death
apoptotic cell
treatment
relates
apoptotic
Prior art date
Application number
PCT/US2001/031992
Other languages
French (fr)
Other versions
WO2002030411A2 (en
Inventor
Eduardo Marban
Brian O'rourke
Massaharu Akao
Andreas Ohler
Original Assignee
Univ Johns Hopkins
Eduardo Marban
Brian O'rourke
Massaharu Akao
Andreas Ohler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Eduardo Marban, Brian O'rourke, Massaharu Akao, Andreas Ohler filed Critical Univ Johns Hopkins
Priority to AU2002213174A priority Critical patent/AU2002213174A1/en
Publication of WO2002030411A2 publication Critical patent/WO2002030411A2/en
Publication of WO2002030411A8 publication Critical patent/WO2002030411A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine

Abstract

L'invention concerne de nouvelles méthodes permettant de traiter la mort apoptotique des cellules, notamment la mort apoptotique des cellules cardiaques et neuronales. L'invention concerne également des thérapies consistant à administrer un composé oxydant mitochondrial à un sujet qui en a besoin, notamment à un sujet souffrant ou susceptible de souffrir d'accident cérébrovasculaire, de crise cardiaque, de traumatisme du cerveau ou de la moelle épinière, ou de troubles chroniques pouvant résulter de la mort apoptotique des cellules tels que les maladies neurodégénératives et les diabètes.The invention relates to novel methods for treating apoptotic cell death, including apoptotic death of heart and neuronal cells. The invention also relates to therapies comprising administering a mitochondrial oxidative compound to a subject in need thereof, in particular to a subject suffering from or liable to suffer from stroke, heart attack, trauma to the brain or spinal cord, or chronic disorders that may result from apoptotic cell death such as neurodegenerative diseases and diabetes.

PCT/US2001/031992 2000-10-13 2001-10-15 Treatment of apoptotic cell death WO2002030411A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002213174A AU2002213174A1 (en) 2000-10-13 2001-10-15 Treatment of apoptotic cell death

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24026700P 2000-10-13 2000-10-13
US60/240,267 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002030411A2 WO2002030411A2 (en) 2002-04-18
WO2002030411A8 true WO2002030411A8 (en) 2002-07-11

Family

ID=22905851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031992 WO2002030411A2 (en) 2000-10-13 2001-10-15 Treatment of apoptotic cell death

Country Status (3)

Country Link
US (1) US6521617B2 (en)
AU (1) AU2002213174A1 (en)
WO (1) WO2002030411A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100492252B1 (en) * 2002-08-09 2005-05-30 한국화학연구원 Benzopyran derivatives substituted with secondary amines including imidazole and their preparation
WO2004071458A2 (en) * 2003-02-13 2004-08-26 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
JP2008510835A (en) * 2004-08-25 2008-04-10 エッセンシャリス，インク． Pharmaceutical formulation of potassium ATP channel opener and use thereof
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
AU2006335153B2 (en) 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US20090076095A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched nicorandil
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
EP2422787A1 (en) * 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183948B1 (en) * 1998-04-15 2001-02-06 Johns Hopkins University Methods to identify compounds affecting mitochondria
AU1338801A (en) * 1999-10-22 2001-05-08 Wake Forest University Methods of protecting neuronal function

Also Published As

Publication number Publication date
US6521617B2 (en) 2003-02-18
US20020091144A1 (en) 2002-07-11
WO2002030411A2 (en) 2002-04-18
AU2002213174A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
WO2005006945A3 (en) Methods for treating neural disorders and compounds useful therefor
PT751766E (en) NASAL AND OCULAR ADMINISTRATION OF CETAMINE TO MANAGE PAIN AND DETOXIFICATION
WO2004014953A3 (en) Anti-myelin associated glycoprotein (mag) antibodies
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
ATE355374T1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES
DE69333775D1 (en) SYNTHETIC CATALYTIC FREE RADICAL RECIPIENTS, USED AS ANTIOXIDANTS FOR THE PREVENTION AND THERAPY OF DISEASES
WO1996032092A3 (en) Cleansing emulsions
WO2005003766A3 (en) Methods of regulating metabolism and mitochondrial function
EP1688425A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
ATE266417T1 (en) MEDICATIONS FOR PREVENTING OR TREATING VASCULAR HEMORRHAGIA
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
DE69717148D1 (en) 3-PYRIDYLENE ANTIOMERS AND THEIR USE AS ANALGETICS
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2002030411A8 (en) Treatment of apoptotic cell death
AU2001238034A1 (en) Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
MA27539A1 (en) NEW SYNERGISTIC COMBINATION CONTAINING ROFLUMILAST AND FORMOTEROL
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
DE60018554D1 (en) MEDICAMENT FOR PROMOTING NEURONAL CELL DIFFERENTIATION CONTAINING CYCLIC GLYCEROPHOSPHATES AND THEIR ANALOGUES
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
CA2140010A1 (en) Blood coagulation normalizer containing tcf-ii as active ingredient
EA200400535A1 (en) SUPPRESSION OF VIRUSES N-DOCOSANOL
WO2000001440A3 (en) Methods for treating neurological injuries and disorders
BR9612123A (en) Compositions containing bismuth and one or more antimicrobials for the prevention of gastrointestinal disorders
CA2239433A1 (en) Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

D17 Declaration under article 17(2)a
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP